CHD2 (Chromodomain Helicase DNA Binding Protein 2) encodes a chromatin remodeling enzyme belonging to the CHD family. CHD2 hydrolyzes ATP to slide, reposition, or eject nucleosomes, thereby regulating gene expression by modulating DNA accessibility. CHD2 plays important roles in neuronal development, synaptic plasticity, and circadian rhythm regulation. Heterozygous CHD2 mutations are associated with intellectual disability, autism spectrum disorder, and epilepsy, while somatic mutations occur in cancers.
CHD2 (Chromodomain Helicase DNA Binding Protein 2) is a member of the CHD (Chromodomain Helicase DNA-binding) family of ATP-dependent chromatin remodelers. CHD2 plays crucial roles in regulating gene expression during neural development and maintaining neuronal function.
CHD2 utilizes the energy from ATP hydrolysis to slide, evict, or restructure nucleosomes, thereby modulating DNA accessibility for transcription factors and RNA polymerase II. Unlike other CHD family members, CHD2 has unique functions in:
- Neurodevelopment: Regulating genes critical for brain development, neuronal differentiation, and synapse formation
- Epigenetic regulation: Depositing histone modifications and maintaining chromatin states
- DNA damage response: Participating in repair of double-strand breaks
CHD2 contains several functional domains:
- N-terminal tandem chromodomains: Recognize histone modifications (H3K4me3, H3K27me3)
- Central SNF2 ATPase domain: Hydrolyzes ATP for chromatin remodeling
- C-terminal DNA-binding domain: Binds DNA and nucleosomal DNA
The remodeling cycle involves:
- Recognition: Chromodomains bind modified histones at target loci
- Recruitment: ATPase domain activated at nucleosomal DNA
- Remodeling: ATP hydrolysis drives nucleosome translocation
- Release: Remodeled nucleosome repositioned or evicted
CHD2 regulates neuronal genes through:
- Activity-dependent remodeling: Immediate-early gene activation
- Synaptic plasticity: Reorganization of synaptic gene loci
- Circadian regulation: Clock gene chromatin remodeling
CHD2 is highly expressed in the brain, particularly in:
CHD2 mutations are among the most common genetic causes of epilepsy. De novo pathogenic variants in CHD2 cause:
- Early-onset epileptic encephalopathies: Seizure onset typically between 6 months and 4 years
- Photosensitive epilepsy: Many patients exhibit abnormal photoparoxysmal responses
- Myoclonic-atonic seizures: Characteristic seizure types
- Developmental regression: Cognitive decline following seizure onset
The mechanism involves disrupted chromatin remodeling at genes critical for neuronal excitability and synaptic function.
CHD2 haploinsufficiency is associated with:
- Intellectual disability (mild to moderate)
- Autism spectrum disorder features
- Attention deficit hyperactivity disorder (ADHD)
- Speech delay and language impairment
Recent studies have identified CHD2 mutations in ALS patients, suggesting a role in:
- Motor neuron degeneration
- RNA metabolism dysregulation
- Chromatin remodeling defects in motor neurons
CHD2 mutations lead to epilepsy through:
- Dysregulated neuronal excitability: Altered ion channel gene expression
- Synaptic dysfunction: Impaired GABAergic signaling
- Developmental abnormalities: Disrupted neural circuit formation
CHD2 deficiency contributes to neurodegeneration via:
- Transcriptional dysregulation: Impaired activity-dependent gene programs
- DNA damage accumulation: Defective chromatin repair
- Cell cycle re-entry: Aberrant cell cycle activation in post-mitotic neurons
CHD2 represents a potential therapeutic target through:
- Epigenetic modulators: Small molecules targeting CHD2 activity
- Gene therapy: Restoring proper CHD2 expression
- Symptomatic treatment: Managing seizures and developmental symptoms
- Carvill GL et al., CHD2 mutations in epileptic encephalopathy (2013)
- Suls A et al., De novo CHD2 mutations in Dravet syndrome (2013)
- Kong W et al., CHD2 promotes neuronal excitability (2022)
- Charroux B et al., CHD2 in neural development (2018)